Please assess the completion status of the following clinical trial:

Trial Title: Placebo Controlled Trial of Bosentan in Scleroderma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* SSc patients \> 18 with NYHA functional Class I/II symptoms, informed consent, and who are willing to participate in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) long term study (Georgetown IRB 04-227)~* Right heart catheterization with~  1. Normal Mean Pulmonary Arterial Pressure (PAP) at rest~ 2. Mean PAP \> 30 with exercise~ 3. Wedge Pressure \< 18~* Entry criteria for participating in the exercise echocardiogram study (Georegtown IRB 03-363)~  1. Diffusing Capacity (DLCO) \<60 with a Forced Vital Capacity (FVC) \>60%, or~ 2. FVC/DLCO \> 1.6, or~ 3. a resting Pulmonary Arterial Systolic Pressure (PASP)\> 40mmHg~Exclusion Criteria:~* Established resting pulmonary hypertension~* Congestive heart failure~* Diastolic dysfunction~* Pregnancy~* Inability to adequately walk/exercise~* Severe liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bosentan (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).